How big is Voyager Therapeutics, Inc.?

As of Jun 18, Voyager Therapeutics, Inc. has a market capitalization of 172.65 million, with net sales of 66.96 million and a net loss of 84.69 million over the latest four quarters. Shareholder's funds were 299.76 million, and total assets amounted to 393.05 million as of Dec 24.

As of Jun 18, Voyager Therapeutics, Inc. has a market capitalization of 172.65 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 66.96 million for the latest four quarters, while the net profit for the same period was a loss of 84.69 million.<BR><BR>As of Dec 24, the company's shareholder's funds were 299.76 million, and total assets amounted to 393.05 million.

What does Voyager Therapeutics, Inc. do?

Voyager Therapeutics, Inc. is a clinical-stage gene therapy company focused on treating severe central nervous system diseases. As of March 2025, it reported net sales of $6 million and a net loss of $31 million, with a market cap of $172.65 million.

Overview: <BR>Voyager Therapeutics, Inc. is a clinical-stage gene therapy company focused on developing treatments for severe diseases of the central nervous system (CNS) within the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 6 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -31 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 172.65 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.84 <BR>Return on Equity: -31.06% <BR>Price to Book: 0.63<BR><BR>Contact Details: <BR>Address: 75 Sidney St, CAMBRIDGE MA: 02139-4134 <BR>Tel: 1 857 2595340 <BR>Website: https://www.voyagertherapeutics.com/

Should I buy, sell or hold Voyager Therapeutics, Inc.?

Who are in the management team of Voyager Therapeutics, Inc.?

As of March 2022, the management team of Voyager Therapeutics, Inc. includes G. Andre Turenne as President and CEO, Nancy Vitale as a Director, and James Geraghty and Dr. Steven Hyman as Independent Directors.

As of March 2022, the management team of Voyager Therapeutics, Inc. includes Mr. G. Andre Turenne, who serves as the President, Chief Executive Officer, and Director. Additionally, Ms. Nancy Vitale is a Director, while Mr. James Geraghty and Dr. Steven Hyman are both Independent Directors.

Is Voyager Therapeutics, Inc. overvalued or undervalued?

As of March 11, 2025, Voyager Therapeutics, Inc. is considered risky and overvalued due to negative financial metrics and significant underperformance compared to the S&P 500, with a 1-year return of -28.01% and a negative return on equity of -31.06%.

As of 11 March 2025, the valuation grade for Voyager Therapeutics, Inc. has moved from expensive to risky, indicating a significant shift in its perceived value. The company appears to be overvalued given its negative financial metrics, with a Price to Book Value of 0.72, an EV to EBIT of 0.32, and an EV to EBITDA of 0.34. Comparatively, peers like Agenus, Inc. have a more favorable EV to EBITDA ratio of -6.0607, suggesting that Voyager is underperforming relative to its industry counterparts.<BR><BR>The stock has shown a mixed performance against the S&P 500, with a 1-week return of 2.40% compared to the index's 1.05%, but it has significantly lagged over longer periods, such as a 1-year return of -28.01% versus 17.14% for the S&P 500. This underperformance reinforces the view that Voyager Therapeutics, Inc. is currently overvalued, particularly in light of its negative return on equity of -31.06%.

Is Voyager Therapeutics, Inc. technically bullish or bearish?

As of September 12, 2025, Voyager Therapeutics shows a neutral technical trend with mixed signals, underperforming the S&P 500 significantly, with year-to-date and one-year returns of -20.90% and -28.01%, respectively.

As of 12 September 2025, the technical trend for Voyager Therapeutics, Inc. has changed from mildly bullish to sideways. The current technical stance is neutral, with mixed signals across various indicators. The weekly MACD is mildly bullish, while the monthly MACD is bearish. The weekly RSI indicates bearish momentum, contrasting with a bullish monthly RSI. Moving averages on the daily chart are mildly bearish, and the weekly KST is bullish, but the monthly KST is bearish. Dow Theory shows a mildly bullish stance on both weekly and monthly time frames. Overall, the indicators suggest a lack of strong directional momentum.<BR><BR>In terms of performance, Voyager Therapeutics has underperformed the S&P 500 significantly over longer periods, with a year-to-date return of -20.90% compared to the S&P 500's 12.22%, and a one-year return of -28.01% versus the S&P's 17.14%.